AbbVie (ABBV) FCF Margin Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Margin Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-7.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-537.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-911.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
1,568.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
534.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
913.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
9,115.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-1,716.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
-911.00 |
| Dec 31, 2025 |
-1,830.00 |
| Sep 30, 2025 |
-802.00 |
| Jun 30, 2025 |
-167.00 |
| Mar 31, 2025 |
-2,456.00 |
| Dec 31, 2024 |
1,191.00 |
| Sep 30, 2024 |
-1,787.00 |
| Jun 30, 2024 |
-1,960.00 |
| Mar 31, 2024 |
-479.00 |
| Dec 31, 2023 |
-121.00 |
| Sep 30, 2023 |
931.00 |
| Jun 30, 2023 |
1,636.00 |
| Mar 31, 2023 |
-995.00 |
| Dec 31, 2022 |
1,196.00 |
| Sep 30, 2022 |
-178.00 |
| Jun 30, 2022 |
488.00 |
| Mar 31, 2022 |
-212.00 |
| Dec 31, 2021 |
-653.00 |
| Sep 30, 2021 |
231.00 |
| Jun 30, 2021 |
39.00 |
| Mar 31, 2021 |
420.00 |
| Dec 31, 2020 |
198.00 |
| Sep 30, 2020 |
4,511.00 |
| Jun 30, 2020 |
2,956.00 |
| Mar 31, 2020 |
1,211.00 |
| Dec 31, 2019 |
1,476.00 |
| Sep 30, 2019 |
3,106.00 |
| Jun 30, 2019 |
76.00 |
| Mar 31, 2019 |
349.00 |
| Dec 31, 2018 |
1,096.00 |
| Sep 30, 2018 |
1,739.00 |
| Jun 30, 2018 |
-157,143.00 |
| Mar 31, 2018 |
327.00 |
| Dec 31, 2017 |
4,445.00 |
| Sep 30, 2017 |
-3,360.00 |
| Jun 30, 2017 |
-3,360.00 |
| Mar 31, 2017 |
2,002.00 |
| Dec 31, 2016 |
-41.00 |
| Sep 30, 2016 |
-1,490.00 |
| Jun 30, 2016 |
-1,318.00 |
| Mar 31, 2016 |
830.00 |
| Dec 31, 2015 |
1,216.00 |
| Sep 30, 2015 |
-1,617.00 |
| Jun 30, 2015 |
157,202.00 |
| Mar 31, 2015 |
-574.00 |